MANCHESTER, N.H., May 22, 2025 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing state-of-the-art insulin delivery technologies today announced a commercial development agreement for ...

Despite the market's 1.4% decline during the same period, Abbott's announcements, including partnerships and clinical results showcasing reduced hospitalization risks with its glucose monitoring ...

The agreement aims to improve outcomes for people with type 1 diabetes by adding ketone sensing capabilities to a Libre glucose sensor in combination with the twiist AID System to enable earlier ...

Integration of Abbott's glucose-ketone sensor with the twiist™ AID System aims to enhance early identification of rising ketones to detect the risk of diabetic ketoacidosis (DKA)1 MANCHESTER, N.H., ...

Instead, the monitor works via a small sensor placed just below the surface of your skin. You need to place the accompanying screen monitor above the system to get your glucose reading.

Despite the market's 1.4% decline during the same period, Abbott's announcements, including partnerships and clinical results showcasing reduced hospitalization risks with its glucose monitoring ...

Sequel Med Tech announced today that it agreed to integrate its twiist automated insulin delivery system with a future Abbott ...

In the current in vivo study we compared the SCGM system with a commercially available needle type glucose sensor during an oral glucose tolerance test (OGTT) and during physical exercise. The SCGM ...

In this work, we developed a flexible screen-printed amperometric electrochemical NO 3 – sensor functionalized by electrodeposited Cu metal nanoclusters. The uniqueness of the proposed sensor consists ...

Get article recommendations from ACS based on references in your Mendeley library. Pair your accounts.